EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis

Rafael Parra-Medina, Juan Pablo Castañeda-González, Viviana Chaves-Cabezas, Juan Pablo Alzate, Juan José Chaves

Pathology - Research and Practice · 2024

DOI: 10.1016/j.prp.2024.155276 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Rafael Parra-Medina und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia; Department of Pathology, Fundación Universitaria de Cie…. Hauptthemen laut MEDLINE: Mesothelioma, Malignant, Biomarkers, Tumor, Immunohistochemistry, Pleural Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 142 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Malignant pleural mesothelioma (MPM) poses diagnostic challenges due to its resemblance to benign pleural pathologies and different histological subtypes. Several immunohistochemistry markers have been employed to aid in accurate diagnosis. METHODS: The present systematic review and meta-analysis aimed to assess the diagnostic performance of various immunohistochemistry markers in malignant pleural mesothelioma diagnosis and its histological subtypes. Following the PRISMA guidelines, we systematically searched the literature for articles on using different immunohistochemical markers in MPM and its histological subtypes. EMBASE, LILACS, MEDLINE, and Virtual Health Library were searched for studies published up to August 2023. We used the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) criteria to assess the quality of the included articles. Meta-analyses were performed to determine prevalence using a random-effects model. RESULTS: 103 studies met the inclusion criteria, comprising a diverse range of immunohistochemistry markers. EMA and desmin-loss exhibited high sensitivity (96% and 92%, respectively) in distinguishing malignant pleural mesothelioma from benign pleural pathologies. Specificity was notably high for both BAP1-loss and survivin expression at 100%. Subtype-specific analyses demonstrated that EMA and HEG1 were sensitive markers for epithelioid mesothelioma, while GLUT1 showed high sensitivity for sarcomatoid mesothelioma. In cases comparing epithelioid mesothelioma and lung adenocarcinoma, CAM5.2 and calretinin displayed high sensitivity, while WT1 and BAP1-loss demonstrated exceptional specificity for malignant epithelioid mesothelioma. In the case of sarcomatoid mesothelioma and sarcomatoid lung carcinoma, GATA3 exhibited the most heightened sensitivity, while GATA3 and D2-40 displayed the best specificity for sarcomatoid malignant mesothelioma diagnosis. CONCLUSION: Immunohistochemistry markers are essential in accurately diagnosing malignant pleural mesothelioma and its histological subtypes. This systematic review and meta-analysis provide a comprehensive insight into the diagnostic performance of these markers, facilitating their potential clinical utility in the discrimination of malignant pleural mesothelioma from other pleural pathologies and the differentiation of malignant pleural mesothelioma subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesothelioma, MalignantBiomarkers, TumorImmunohistochemistryPleural NeoplasmsHumansLung NeoplasmsDiagnosis, Differential

Stichwörter der Autor:innen

ImmunohistochemistryLung neoplasmsMesotheliomaPleural neoplasms

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Research Institute, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia; Department of Pathology, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia; Department of Pathology, I…
  • Research Institute, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia; Department of Pathology, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia. Electronic address: jpcast…
  • Department of Pathology, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia. Electronic address: mvchaves@fucsalud.edu.co.
  • Research Institute, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia. Electronic address: jpalzate@fucsalud.edu.co.
  • Department of Medicine, Norwalk Hospital, Yale School of Medicine, Norwalk, CT, United States. Electronic address: juan-chavescabezas@hotmail.com.

Zitieren

APA

Parra-Medina, R., Castañeda-González, J. P., Chaves-Cabezas, V., Alzate, J. P., & Chaves, J. J. (2024). Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155276

Vancouver

Parra-Medina R, Castañeda-González JP, Chaves-Cabezas V, Alzate JP, Chaves JJ. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155276

BibTeX
@article{ParraMedina2024,
  author = {Parra-Medina, Rafael and Castañeda-González, Juan Pablo and Chaves-Cabezas, Viviana and Alzate, Juan Pablo and Chaves, Juan José},
  title = {Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis},
  journal = {Pathology - Research and Practice},
  year = {2024},
  doi = {10.1016/j.prp.2024.155276}
}
Kostenlos starten →